Reported 1 day ago
Truist has increased its price target on Alnylam (ALNY) from $459 to $535 while maintaining a Buy rating on the stock before the company's Q3 results. The firm also raised its Q3 sales estimate for Amvuttra to $690 million, attributing the increase to strong early adoption and feedback from prescribers noting more widespread extracardiac manifestations of ATTR-CM.
Source: YAHOO